Kiniksa Pharmaceuticals Ltd (KNSA)vsTeva Pharma Industries Ltd ADR (TEVA)
KNSA
Kiniksa Pharmaceuticals Ltd
$45.84
+2.00%
HEALTHCARE · Cap: $3.44B
TEVA
Teva Pharma Industries Ltd ADR
$29.46
+1.10%
HEALTHCARE · Cap: $33.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates 2447% more annual revenue ($17.26B vs $677.56M). KNSA leads profitability with a 8.7% profit margin vs 8.2%. TEVA trades at a lower P/E of 24.1x. TEVA earns a higher WallStSmart Score of 73/100 (B).
KNSA
Buy51
out of 100
Grade: C-
TEVA
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.1%
Fair Value
$35.10
Current Price
$45.84
$10.74 premium
Margin of Safety
+39.4%
Fair Value
$56.63
Current Price
$29.46
$27.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.0% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 21 in profit
Strong operational efficiency at 27.3%
Earnings expanding 40.0% YoY
Generating 1.0B in free cash flow
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, Debt/Equity. Revenue growth of 65.0% demonstrates continued momentum.
Bull Case : TEVA
The strongest argument for TEVA centers on Return on Equity, Operating Margin, EPS Growth. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.43 suggests the stock is reasonably priced for its growth.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 59.9x leaves little room for execution misses.
Bear Case : TEVA
The primary concerns for TEVA are Altman Z-Score.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.
TEVA carries more volatility with a beta of 0.72 — expect wider price swings.
KNSA is growing revenue faster at 65.0% — sustainability is the question.
TEVA generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
TEVA scores higher overall (73/100 vs 51/100) and 11.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing transformative therapies to meet significant unmet medical needs. Its leading candidate, KPL-404, is a targeted monoclonal antibody designed to inhibit B and T lymphocyte activity, offering new therapeutic avenues for various autoimmune disorders. With a strong pipeline and a commitment to scientific excellence, Kiniksa is well-positioned for growth, supported by strategic collaborations and ongoing clinical trials. The company's efforts could potentially redefine treatment paradigms within the biopharmaceutical sector, making it an attractive investment opportunity for institutional investors.
Visit Website →Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?